NCT06856850View on ClinicalTrials.gov

Disease Biosignatures in ALS/FTD Spectrum: New Impactful Biological Perspectives Beyond Clinical Approaches

Not yet recruitingOBSERVATIONAL

Enrollment

230

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions

ALS (Amyotrophic Lateral Sclerosis)FTDNeuropathicPsychiatric DisordersIdiopathic Intracranial HypertensionFrontotemporal Dementia (FTD)

Trial Locations (4)

20133

Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan

50019

Consorzio Interuniversitario Risonanze Magnetiche Metallo Proteine (CIRMMP), Sesto Fiorentino

80131

"Università degli Studi di Napoli Federico II", Napoli

07100

Azienda Ospedaliero Universitaria di Sassari, Sassari

All Listed Sponsors

lead

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

OTHER

NCT06856850 - Disease Biosignatures in ALS/FTD Spectrum: New Impactful Biological Perspectives Beyond Clinical Approaches | Biotech Hunter | Biotech Hunter